Literature DB >> 17353914

Point-of-care PSA testing: an evaluation of PSAwatch.

O Karim1, A Rao, M Emberton, D Cochrane, M Partridge, P Edwards, I Walker, I Davidson.   

Abstract

We present a new quantitative prostate-specific antigen (PSA) assay using a portable, point-of-care test (PSAwatch) and reader system (BioScan) for measuring PSA concentrations in the range from 0.5 to < or =25 microg/l. Blood samples from patients (n=199) were submitted for laboratory PSA and also evaluated using PSAwatch and the BioScan system. PSA concentrations in 188 men were < or =25 microg/l and studied. Correlation between the two methods was good (R(2)=0.88) with a standard error of 1.588. The regression line had a bias of -0.02 at the concentration of 4.00 microg/l. This is the first report of a quantitative, portable, point-of-care PSA test and reader system. PSAwatch may reduce the number of hospital visits for patients with prostate disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353914     DOI: 10.1038/sj.pcan.4500962

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  3 in total

1.  Prostate Cancer Education, Detection, and Follow-Up in a Community-Based Multiethnic Cohort of Medically Underserved Men.

Authors:  Omotola S Ashorobi; Jacqueline Frost; Xuemei Wang; Pamela Roberson; E Lin; Robert J Volk; David S Lopez; Lovell A Jones; Curtis A Pettaway
Journal:  Am J Mens Health       Date:  2016-07-08

2.  Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.

Authors:  Agnieszka Maj-Hes; Sabina Sevcenco; Tibor Szarvas; Gero Kramer
Journal:  Adv Ther       Date:  2019-02-18       Impact factor: 3.845

3.  Assessment of a new point-of-care system for detection of prostate specific antigen.

Authors:  Steffen Rausch; Joerg Hennenlotter; Josef Wiesenreiter; Andrea Hohneder; Julian Heinkele; Christian Schwentner; Arnulf Stenzl; Tilman Todenhöfer
Journal:  BMC Urol       Date:  2016-01-19       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.